Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery. Issue 1 (December 2017)
- Record Type:
- Journal Article
- Title:
- Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery. Issue 1 (December 2017)
- Main Title:
- Impact of gut hormone FGF-19 on type-2 diabetes and mitochondrial recovery in a prospective study of obese diabetic women undergoing bariatric surgery
- Authors:
- Martinez de la Escalera, Lucia
Kyrou, Ioannis
Vrbikova, Jana
Hainer, Voitech
Sramkova, Petra
Fried, Martin
Piya, Milan
Kumar, Sudhesh
Tripathi, Gyanendra
McTernan, Philip - Abstract:
- Abstract Background The ileal-derived hormone, fibroblast growth factor 19 (FGF-19), may promote weight loss and facilitate type-2 diabetes mellitus remission in bariatric surgical patients. We investigated the effect of different bariatric procedures on circulating FGF-19 levels and the resulting impact on mitochondrial health in white adipose tissue (AT). Methods Obese and type-2 diabetic women (n = 39, BMI > 35 kg/m2 ) undergoing either biliopancreatic diversion (BPD), laparoscopic greater curvature plication (LGCP), or laparoscopic adjustable gastric banding (LAGB) participated in this ethics approved study. Anthropometry, biochemical, clinical data, serum, and AT biopsies were collected before and 6 months after surgery. Mitochondrial gene expression in adipose biopsies and serum FGF-19 levels were then assessed. Results All surgeries led to metabolic improvements with BPD producing the greatest benefits on weight loss (↓30%), HbA1c (↓28%), and cholesterol (↓25%) reduction, whilst LGCP resulted in similar HbA1c improvements (adjusted for BMI). Circulating FGF-19 increased in both BPD and LGCP (χ2 (2) = 8.088;P = 0.018), whilst, in LAGB, FGF-19 serum levels decreased (P = 0.028). Interestingly, circulating FGF-19 was inversely correlated with mitochondrial number in AT across all surgeries (n = 39). In contrast to LGCP and LAGB, mitochondrial number in BPD patients corresponded directly with changes in 12 of 14 mitochondrial genes assayed (P < 0.01). ConclusionsAbstract Background The ileal-derived hormone, fibroblast growth factor 19 (FGF-19), may promote weight loss and facilitate type-2 diabetes mellitus remission in bariatric surgical patients. We investigated the effect of different bariatric procedures on circulating FGF-19 levels and the resulting impact on mitochondrial health in white adipose tissue (AT). Methods Obese and type-2 diabetic women (n = 39, BMI > 35 kg/m2 ) undergoing either biliopancreatic diversion (BPD), laparoscopic greater curvature plication (LGCP), or laparoscopic adjustable gastric banding (LAGB) participated in this ethics approved study. Anthropometry, biochemical, clinical data, serum, and AT biopsies were collected before and 6 months after surgery. Mitochondrial gene expression in adipose biopsies and serum FGF-19 levels were then assessed. Results All surgeries led to metabolic improvements with BPD producing the greatest benefits on weight loss (↓30%), HbA1c (↓28%), and cholesterol (↓25%) reduction, whilst LGCP resulted in similar HbA1c improvements (adjusted for BMI). Circulating FGF-19 increased in both BPD and LGCP (χ2 (2) = 8.088;P = 0.018), whilst, in LAGB, FGF-19 serum levels decreased (P = 0.028). Interestingly, circulating FGF-19 was inversely correlated with mitochondrial number in AT across all surgeries (n = 39). In contrast to LGCP and LAGB, mitochondrial number in BPD patients corresponded directly with changes in 12 of 14 mitochondrial genes assayed (P < 0.01). Conclusions Elevated serum FGF-19 levels post-surgery were associated with improved mitochondrial health in AT and overall diabetic remission. Changes in circulating FGF-19 levels were surgery-specific, with BPD producing the best metabolic outcomes among the study procedures (BPD > LGCP > LAGB), and highlighting mitochondria in AT as a potential target of FGF-19 during diabetes remission. … (more)
- Is Part Of:
- BMC medicine. Volume 15:Issue 1(2017)
- Journal:
- BMC medicine
- Issue:
- Volume 15:Issue 1(2017)
- Issue Display:
- Volume 15, Issue 1 (2017)
- Year:
- 2017
- Volume:
- 15
- Issue:
- 1
- Issue Sort Value:
- 2017-0015-0001-0000
- Page Start:
- 1
- Page End:
- 9
- Publication Date:
- 2017-12
- Subjects:
- Gut hormone -- FGF-19 -- Mitochondria -- Type-2 diabetes recovery -- Obesity -- Bariatric surgery
Medicine -- Periodicals
610.5 - Journal URLs:
- http://www.biomedcentral.com/bmcmed/ ↗
http://www.pubmedcentral.nih.gov/tocrender.fcgi?journal=216 ↗
http://link.springer.com/ ↗ - DOI:
- 10.1186/s12916-017-0797-5 ↗
- Languages:
- English
- ISSNs:
- 1741-7015
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 10033.xml